Midazolam Injection from Strides Arcolab Approved by FDA

Drug firm Strides Arcolab received approval from the US health regulator to market Midazolam injections.

Strides Arcolab announced that it had received US FDA approval for Midazolam injection multiple-dose vials.

Midazolam, a general anaesthetic, is given as a sterile, non-pyrogenic parenteral dosage form for intravenous or intramuscular injections.

The injection is expected to be launched under the partnership between Strides and Sagent.

Strides has already received FDA approval for single-dose vials.